Clinical Trials
7 trialsNCT07618923 2026-06-01
TD-DASHER-01
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT05582499 2026-05-28
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT07610720 2026-05-28
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07581834 2026-05-12
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Fujian Cancer Hospital
Phase 2 Recruiting
NCT07539753 2026-04-30
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07492394 2026-04-02
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT06650748 2026-03-17
NeoMARS
Peking University
Phase 2 Enrolling by invitation